Trials of arsenic trioxide therapy should be envisioned for severely respiratory distress syndrome related to a cytokine storm in COVID-19 patients

Authors

François Rieger CEO, Medsenic SAS, 204 Avenue de Colmar, 67 100 Strasbourg, France Author

DOI:

https://doi.org/10.33425/2690-8077.1023

Abstract

.

Downloads

Published

2025-07-29

Issue

Section

Articles